BR0316170A - Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer - Google Patents

Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer

Info

Publication number
BR0316170A
BR0316170A BR0316170-6A BR0316170A BR0316170A BR 0316170 A BR0316170 A BR 0316170A BR 0316170 A BR0316170 A BR 0316170A BR 0316170 A BR0316170 A BR 0316170A
Authority
BR
Brazil
Prior art keywords
combination
cancer
pharmaceutical composition
prophylaxis
synergistic treatment
Prior art date
Application number
BR0316170-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan Barge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0316170A publication Critical patent/BR0316170A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0316170-6A 2002-11-13 2003-11-07 Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer BR0316170A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226434.9A GB0226434D0 (en) 2002-11-13 2002-11-13 Combination product
PCT/GB2003/004787 WO2004043472A1 (en) 2002-11-13 2003-11-07 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine

Publications (1)

Publication Number Publication Date
BR0316170A true BR0316170A (pt) 2005-09-27

Family

ID=9947715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316170-6A BR0316170A (pt) 2002-11-13 2003-11-07 Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer

Country Status (16)

Country Link
US (1) US20060142297A1 (enExample)
EP (1) EP1562612B1 (enExample)
JP (1) JP2006508953A (enExample)
KR (1) KR20050074573A (enExample)
CN (1) CN100467027C (enExample)
AT (1) ATE456370T1 (enExample)
AU (1) AU2003279456B2 (enExample)
BR (1) BR0316170A (enExample)
CA (1) CA2504666A1 (enExample)
DE (1) DE60331162D1 (enExample)
ES (1) ES2338109T3 (enExample)
GB (1) GB0226434D0 (enExample)
NO (1) NO20052312L (enExample)
NZ (1) NZ539514A (enExample)
WO (1) WO2004043472A1 (enExample)
ZA (1) ZA200503805B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US7462623B2 (en) * 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
KR20090108086A (ko) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
GB0101599D0 (en) * 2001-01-22 2001-03-07 Novartis Ag Organic compounds
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product

Also Published As

Publication number Publication date
ES2338109T3 (es) 2010-05-04
ATE456370T1 (de) 2010-02-15
EP1562612A1 (en) 2005-08-17
NO20052312L (no) 2005-06-06
WO2004043472A1 (en) 2004-05-27
AU2003279456B2 (en) 2007-05-17
DE60331162D1 (de) 2010-03-18
EP1562612B1 (en) 2010-01-27
GB0226434D0 (en) 2002-12-18
CA2504666A1 (en) 2004-05-27
CN100467027C (zh) 2009-03-11
AU2003279456A1 (en) 2004-06-03
KR20050074573A (ko) 2005-07-18
CN1711094A (zh) 2005-12-21
NZ539514A (en) 2007-11-30
US20060142297A1 (en) 2006-06-29
ZA200503805B (en) 2006-09-27
JP2006508953A (ja) 2006-03-16

Similar Documents

Publication Publication Date Title
GB0226434D0 (en) Combination product
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
BRPI0412919A (pt) combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
BRPI0409742A (pt) uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica
MXPA04001397A (es) Metodo y composiciones para el tratamiento y prevencion de dolor e inflamacion con un inhibidor selectivo de cicloxigenasa-2 y sulfato de condroitina.
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.